Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05382299
Title Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer (ASCENT-03)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Gilead Sciences
Indications

triple-receptor negative breast cancer

Therapies

Nab-paclitaxel

Carboplatin + Gemcitabine

Sacituzumab govitecan-hziy

Paclitaxel

Age Groups: adult | senior
Covered Countries USA | FRA | ESP


No variant requirements are available.